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ABSTRACT
OBJECTIVE: The objective of this selective EBM review is to assess if risankizumab is
effective in decreasing the percentage of scaling and body surface area affected amongst those
with moderate to severe plaque psoriasis.
STUDY DESIGN: A review of three peer-reviewed randomized controlled trials published
between 2015-2018.
DATA SOURCES: The three randomized controlled trials were located using the PubMed
database. The studies were selected based upon patient-oriented evidence that matters (POEMs)
in correlation to answering the question proposed.
OUTCOMES MEASURED: Outcomes were measured through the Psoriasis Area Severity
Index Score.
RESULTS: The studies done by Gordon et al., Krueger et al., and Papp et al., all found
statistically significant results (p values < 0.0001, 0.05, and 0.001) when assessing the efficacy
of risankizumab vs comparison groups in decreasing the percentage of scaling and body surface
area affected in patients with moderate to severe plaque psoriasis.
CONCLUSIONS: The evidence presented within the three randomized control trials
demonstrate a statistically significant relationship between risankizumab and its proficiency in
treating the symptoms associated with moderate to severe plaque psoriasis.
KEYWORDS: moderate to severe plaque psoriasis and Risankizumab
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Introduction
One potentially debilitating dermatologic condition that affects many individuals
worldwide is psoriasis. It is a chronic inflammatory dermatologic disease that has both genetic
and autoimmune traits.1 It affects 7.6 million Americans.2 There are several subtypes of the
disease, which are known as psoriasis vulgaris, inverse psoriasis, guttate psoriasis, pustular
psoriasis, and erythrodermic psoriasis. The most prevalent is psoriasis vulgaris, synonymously
called the plaque-type psoriasis. Approximately 90% of psoriasis cases diagnosed are of the
chronic plaque psoriasis type.1 Chronic plaque psoriasis often clinically manifests as sharply
demarcated, erythematous pruritic plaques covered in silvery scales which can coalesce and
cover a vast percentage of body surface area.
Although psoriasis primarily presents as skin manifestations of plaques, there are also
comorbidities associated with the condition due to its inflammatory autoimmune
pathophysiology. There is still much to be learned about psoriasis, but it is thought to be caused
by a defect in the body’s TNFα-IL23-Th17 axis which regulates immune and inflammatory
processes. This axis plays an important role in T cell mediated plaque psoriasis.1 It has been
hypothesized that overexpression of the inflammatory process leads to chronicity of plaque
psoriasis and systemic comorbidities.1
Those who are diagnosed with psoriasis have a 40% chance of developing psoriatic
arthritis, this is due to psoriatic inflammation of the joints.1 Studies have also revealed that
patients with severe chronic psoriasis are also at an increased risk of myocardial infarctions,
coronary artery disease, and renal disease.1 There has also been evidence that demonstrates a
higher prevalence of suicidal ideation amongst those with severe chronic plaque psoriasis due to
the silvery scales covering large portions of a patient’s skin, diminishing their self-confidence.1
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There is medication available to treat moderate to severe plaque psoriasis and to help improve
the patient’s quality of life but they can be quite expensive. The monoclonal antibodies and
biologics that are often prescribed are estimated to be $95,000-100,000 per person annually.3
Patients who have less severe cases of plaque psoriasis only requiring phototherapy are estimated
to spend $3,000-7,200 per year.4
This skin condition affects many Americans and one study found that 50% of their survey
respondents who had plaque psoriasis reported going to their dermatologist annually and 3%
reported going to an ambulatory clinic annually.5 It is possible that because the disease has no
cure patients who have plaque psoriasis may visit their providers less frequently. It has been
demonstrated how disabling the condition can be and though there are medications such as
biologics, furamic acid esters, phosphodiesterase-4 inhibitors, TNFα inhibitors, and monoclonal
antibodies used to treat the condition, there has been a proposal of a new monoclonal antibody
that may be more efficacious than other therapeutics in treating the symptoms associated with
moderate to severe plaque psoriasis.
The new monoclonal antibody is risankizumab. There have been three randomized
controlled trials (RCTs) conducted that assess the medication’s proficiency in relation to
comparison groups in treating symptoms of moderate to severe plaque psoriasis such as scaling,
and percentage of body surface area affected.6,7,8 If this medication is deemed to be more
efficacious in alleviating the patient’s symptoms in comparison to others, then this may
ultimately lead to the patient having an increased quality of life and it could also improve rapport
within the patient-provider relationship. Therefore, these trials will be further discussed to
evaluate this possibility.
Objective
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The objective of this selective EBM review is to determine whether risankizumab
efficiently decreases scaling and percentage of body surface area affected within adults who have
moderate to severe plaque psoriasis.
Methods
Criteria used for selection of studies:
The population specifically focused on within this review is adults older than 18 with
moderate to severe plaque psoriasis who have a high percentage of body surface area affected by
the disease. The three peer-reviewed randomized controlled trials being discussed conducted
their studies amongst this population.6,7,8 Risankizumab is the monoclonal antibody that is being
assessed as an intervention regarding it’s efficacy in reducing scaling and the percentage of body
surface area affected amongst those with moderate to severe plaque psoriasis. The randomized
controlled trials used the Psoriasis Area Severity Index (PASI) Score, which can measure the
reduction of total body surface area involvement, to assess the drug’s effectiveness in decreasing
symptoms.6,7,8
Gordon et al. compared 150 mg of risankizumab to 45 or 90 mg of ustekinumab and 150
mg of risankizumab to a placebo for 52 weeks to further determine this.6 Krueger et al. compared
a single dose of risankizumab at 0.01, 0.05, 0.25, 1, 3, or 5mg/kg IV or subcutaneous to a
placebo within their study to assess the drug’s proficiency.7 Papp et al. compared subcutaneous
injections of risankizumab of 18 mg – 180 mg (dependent upon the week of the study) vs. 45 –
90 mg (according to body weight) of ustekinumab to evaluate risankizumab’s potential in
reducing symptoms.8 The participants of studies began with a PASI baseline of 12 or greater and
percentage of body surface area affected of 10% or greater.6,7,8
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Table 1. - Demographics and Characteristics of Included Studies
Study

Type

# Pts

Gordon
et al.
2018
(6)

RCT

506

Krueger
et al.
2015
(7)

RCT

39

Papp et
al. 2017
(8)

RCT

166

Age(yrs)

Inclusion
Criteria
>18 yrs
Patients
older
than 18
with
stable
chronic
moderate
to severe
plaque
psoriasis
18-75 yrs Patients
with
moderate
to severe
chronic
plaque
psoriasis
for at
least 6
months.

18-75
years

Patients
between
the ages
of 18-75
who
were
stable
with
moderate
to severe
chronic
plaque.

Exclusion
Criteria
Individuals
who could
not undergo
systemic or
phototherapy
and were
ineligible for
treatment
with
ustekinumab
Female
subjects of
childbearing
potential or
if they had
received
prior
treatment
with
ustekinumab
within 24
weeks, other
biologic
agents, or
psoralen,
and UVA
within 12
weeks.
Patients who
previously
had
ustekinumab
or any other
agent
targeting
interleukin12 or
interleukin23.

W/D

Interventions

29

150 mg of
risankizumab
vs. 45 or 90
mg of
ustekinumab
150 mg of
risankizumab
vs. placebo

1

Single dose
of
risankizumab
0.01, 0.05,
0.25, 1, 3, or
5mg/kg IV or
subcutaneous
vs placebo

11

Subcutaneous
injections of
risankizumab
18 mg – 180
mg dose
(dependent
upon the
week of the
study) vs. 45
– 90 mg
(according to
body weight)
of
ustekinumab
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Data Sources:
The three peer-reviewed randomized controlled trials were found using PubMed and
Google Scholar databases. They were all originally published in English. The keywords that
were used when searching for the RCTs were risankizumab and moderate to severe plaque
psoriasis. Studies that were not peer-reviewed and had a substantial number of confounding
variables were disqualified from selection. Studies were selected based upon if they were
published within the past five years and also if they included patient-oriented evidence that
matters (POEMs) in correlation to if risankizumab is an effective treatment compared to other
monoclonal antibodies in reducing percentage of body surface area affected by moderate to
severe plaque psoriasis. The summary of the statistics used within the RCTs to accurately assess
this were NNT, CER, EER, RBI, ABI, and p-value.6,7,8
Outcomes Measured
The Psoriasis Area Severity Index Score was how the patient-oriented outcomes were
measured within the randomized controlled trials.6,7,8 Papp et al. states that the PASI score is
ultimately a comprehensive assessment relating to erythema, induration, scaling and percentage
of body surface area affected.8 A reduction in the PASI score was documented as PASI100,
PASI90, PASI75, and PASI50 throughout the studies pertaining to the participant’s outcomes
after the RCTs were complete.6,7,8 The number after PASI demonstrates the total reduction in
erythema, induration, scaling, and percentage compared to the participant’s baseline PASI
score.6,7,8 For example, if one of the participants within the studies had a baseline PASI score of
15 and they completed the study as PASI90 this demonstrates a 90% reduction in their original
score. We will go on to further review the studies and discuss how they display risankizumab’s
role relating to the reduction of the PASI score.
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Results
In the double-blind, randomized, placebo-controlled trial conducted by Gordon et al.
there were two groups that were involved. The first group included patients who were randomly
assigned to receive 150 mg of risankizumab or 45 or 90 mg of ustekinumab.6 The second group
included patients who were randomly assigned to receive 150 mg of risankizumab or 45 mg or
90 mg of ustekinumab.6 The trial ended at 52 weeks and was conducted at 139 sites which
included hospitals, university medical centers, clinical research units, and private practices.6 The
mean baseline PASI score was 20.6
At 16 weeks within both groups PASI90 was achieved by 75.3% of patients treated with
risankizumab, compared to 42% treated with ustekinumab.6 Dermatologic presentations of
psoriasis were also found to completely resolve (PASI100) among some patients taking
risankizumab when compared to ustekinumab.6 Among the patients that were taking
risankizumab 35.9% achieved PASI100 compared to 12% of those taking ustekinumab.6
Between the groups there was a statistically significant difference found regarding the efficacy of
risankizumab compared to ustekinumab in reducing symptoms of patients with moderate to
severe plaque psoriasis; p value of < 0.0001 was determined.6
The study conducted by Krueger et al. was also a double-blind, randomized, placebocontrolled trial. There was a total of 39 patients included in this 24 week study which took place
in 8 different centers.7 Patients were given 0.01, 0.05, 0.25, 1, 3, or 5 mg/kg of risankizumab
intravenously (n=18), 0.25 or 1mg/kg of risankizumab subcutaneously (n=13), or placebo (n=8).7
Mean PASI score was between 15.7-22.8.7 The PASI reduction score was shown to be higher in
those receiving risankizumab subcutaneously compared to those receiving it intravenously.7
According to Kruger et al., at 24 weeks among patients who were receiving risankizumab
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intravenously or subcutaneously at doses of 0.25mg/kg and higher 84%, 60%, and 36% achieved
PASI75, PASI90, or PASI100 when compared to placebo.7 The study demonstrated that the
placebo had no effect on the PASI score.7 Between risankizumab and the placebo there was
statistically significant difference regarding the aptitude of risankizumab compared to the
placebo in reducing scaling, erythema, induration, and percentage of body surface area affected
within patients who had moderate to severe plaque psoriasis; p value of <0.05 was determined.7
The study conducted by Papp et al. included 166 patients who received either 18-180 mg
per week of risankizumab subcutaneously or 45-90 mg of ustekinumab.8 The study was
conducted at 32 sites and was over the course of 48 weeks.8 The mean PASI score was 12 within
the sample.8 Risankizumab was shown to be more efficient than ustekinumab at week 12 where
PASI90 was achieved in 77% of patients being treated with risankizumab, whereas only 40% of
those being treated with ustekinumab achieved PASI90 at week 12.8 In the study Papp et al. also
displayed how risankizumab was more efficacious than ustekinumab even in lower doses.8 Also,
patients who were receiving risankizumab were demonstrating a superior ability compared to
those receiving ustekinumab to achieve PASI100 at week 12.8 This was shown by 45% of
patients receiving risankizumab achieving PASI100 compared to 18% amongst those taking
ustekinumab.8 Ultimately, statistical significance was found between risankizumab and
ustekinumab regarding risankizumab’s superiority in reducing symptoms of patients with
moderate to severe plaque psoriasis; p value of < 0.001 was found.8
Although the studies reviewed exhibit substantial evidence regarding risankizumab’s
effectiveness in treating symptoms related to moderate to severe plaque psoriasis, there is still
much to be learned about the drug. Krueger et al. revealed that four participants with
predisposing health risks had severe adverse reactions after taking the drug.7 According to Papp
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et al. some participants developed serious adverse reactions as well after taking the drug, which
included basal cell carcinoma, myocardial infarction, and cerebrovascular accidents.8 These
patients accounted for 5/166 participants.8 It is possible that safety may be of concern within
certain populations after taking the drug. Table 2 demonstrates the experimental event rate
(EER), relative benefit increase (RBI), absolute benefit increase (ABI), numbers needed to treat
(NNT), control event rate (CER), and p-value of all three studies.
Table 2 – Summary of Statistics Reported
Study

EER

RBI

ABI

NNT

CER

P-value

Gordon et
al. 2018
(6)

.753

.79

.333

4

.42

<0.0001

Krueger
.85
et al. 2015
(7)

undefined

.85

2

0

<0.05

Papp et al. .73
2017
(8)

.83

.33

4

.42

<0.001

Discussion
Although risankizumab was approved by the FDA in 2019, it is a still a very new
monoclonal antibody and there is still much to be learned about it. While researching the
monoclonal antibody, there were articles discovered pertaining to the possibility of risankizumab
treating inflammatory bowel disease, hidradenitis suppurativa, as well as moderate to severe
plaque psoriasis. Due to the drug being in its infancy this allows for limitations within this
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review. As mentioned previously, a small number of patients who have taken the drug have
developed severe adverse reaction.7,8 It has not been well-established as to whether these adverse
reactions are something to critically be concerned about. Ultimately, being unable to provide
proper information regarding the safety of consuming the medication in certain populations
provides opportunity for limitations of the review.
Conclusion
Overall, the randomized controlled trials that were reviewed allowed for much
clarification regarding the question originally proposed. Individuals affected by moderate to
severe plaque psoriasis live through tumultuous circumstances each day. The monoclonal
antibody risankizumab has demonstrated much proficiency in being able to provide relief to
individuals suffering from the disease. The evidence discussed from the RCTs provide an answer
to the question of if risankizumab is effective in decreasing symptoms associate with moderate to
severe plaque psoriasis. The answer has been shown to be “yes”. The three randomized
controlled trials discussed display risankizumab’s dominance over ustekinumab in treating
moderate to severe plaque psoriasis. There was statistically significant data revealed in each
study reviewed. Risankizumab is a drug by which individuals affected by moderate to severe
psoriasis can look to to provide them with relief of their symptoms which ultimately include
erythema, induration, scaling, and percentage of body surface area affect. Risankizumab has
been demonstrated to be a promising treatment for those who have be debilitated by moderate to
severe plaque psoriasis and it can be looked to as a source of hope within this population.
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